Compounds selectively inhibiting gamma 9 delta 2 T lymphocytes
AssigneesInstitut National de la Sante et de la Recherche Medicale, SangStat Medical Corporation
InventorsChristian Belmant, Marc Bonneville, Marc Alix Peyrat, Jean-Jacquues Fournie, Alan P. Kozikowski
Life of this patent
Estimating the term…
Abstract
The invention concerns compounds of formula CH3—R1—(CH2)2—R2 wherein: R1 is selected among a tertiary alcohol; a 1,2-diol; a halohydrine; an epoxide; an alkene; an aldehyde or an α-hydroxyaldehyde; and R2 is selected among a methylenediphosphonate; a difluoromethylenediphosphonate; or a monofluoromethylenediphosphonate. The invention also concerns the uses of said compounds as selective inhibitors of Tγ9δ2 lymphocytes, and their uses, in particular for therapeutic purposes.
Claims11
A compound having the following formula:
- H3C—R1—CH2)2—R2 (I)
- wherein R1 is selected from the following group consisting of:
- 10
- wherein R3 is H or OH,
- wherein R2 is selected from the group consisting of
- 11
- and wherein Cat+ represents one or more organic or mineral cations, comprising the proton, identical or different, in the same compound, excepting 3-methyl-3-butene-1-yl-difluoromethylenediphosphonate, and 3-methyl-3-butene-1-yl-methylenediphosphonate.
Dependencies are inferred from the claim text.